domingo, 24 de septiembre de 2017

MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - A systematic review and meta-analysis. - PubMed - NCBI

MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - A systematic review and meta-analysis. - PubMed - NCBI



 2017 Sep;214(3):515-524. doi: 10.1016/j.amjsurg.2017.03.049. Epub 2017 Apr 26.

MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - A systematic review and meta-analysis.

Abstract

OBJECTIVES:

The aim of this systematic review and meta-analysis is to summarize the current knowledge regarding microRNA-21 and to evaluate its prognostic impact in patients with pancreatic cancer.

METHODS:

We conducted an electronic literature search to identify all published studies in PubMed/MEDLINE, Scopus and Google Scholar databases from 2000 until August 2016.

RESULTS:

A total of 17 studies involving 1471 patients met the inclusion criteria for the quantitative synthesis. The microRNA-21 upregulation was significantly associated with poorer overall survival, disease-free survival, and progression-free survival. The subgroup analysis revealed that microRNA-21 overexpression has a significant higher prognostic value for patients who receive adjuvant chemotherapy. Increased microRNA-21 was associated with a statistically significant higher rate of metastatic lymph nodes and poorly differentiated tumors.

CONCLUSIONS:

MicroRNA-21 upregulation in pancreatic cancer is associated with a significantly poorer overall survival, disease-free survival, and progression-free survival. MicroRNA-21 may be a useful prognostic biomarker, allowing stratification for chemotherapy administration, and being a component of precision medicine in patients with pancreatic cancer.

KEYWORDS:

Meta-analysis; MicroRNA-21; Pancreatic cancer; Prognosis

PMID:
 
28477839
 
DOI:
 
10.1016/j.amjsurg.2017.03.049

[Indexed for MEDLINE]

No hay comentarios:

Publicar un comentario